Introduction {#Sec1}
============

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine diseases with complex etiology and pathogenesis, with a prevalence of up to 10% in reproductive age women \[[@CR1], [@CR2]\]. It is generally characterized by high androgen, long-term persistent anovulation, and ovarian polycystic changes. Typical clinical manifestations include menstrual disorders, infertility, hypertrichosis, acne, obesity, acanthosisnigricans, and polycystic changes in the ovary detected by ultrasound \[[@CR3]\]. PCOS is often associated with a variety of metabolic diseases involving patients with varying degrees of insulin resistance, hyperinsulinemia and hyperlipidemia \[[@CR4]\]. These metabolic disorders make PCOS patients susceptible to type 2 diabetes, as well as cardiovascular and cerebrovascular diseases \[[@CR5]\]. PCOS accounts for approximately 75% of anovulatory infertility \[[@CR6], [@CR7]\]. The early abortion rate in PCOS patients is as high as 30 to 50%, and the occurrence of recurrent pregnancy loss is also up to 50%, thus seriously affecting the outcome of pregnancy \[[@CR8], [@CR9]\]. The pathogenesis of PCOS, complicated and multifactorial, has not yet been fully elucidated. Currently, it is generally believed that PCOS may be a multi-gene hereditary disorder caused by the interaction of certain genes with environmental factors. Mounting evidence exists that certain genetic polymorphisms play an important role in the pathogenesis of PCOS \[[@CR10]--[@CR13]\].

Vascular endothelial growth factor (VEGF), a homodimeric glycoprotein hormone first purified by Ferrara et al. from the bovine pituitary follicular stellate cells in vitro, is the most active angiogenic factor ever known, which can maintain the differentiation state of vascular endothelial cells and improve microvascular permeability, and play a powerful regulatory role in the occurrence and development of various diseases \[[@CR14], [@CR15]\]. It is closely related to the pathogenesis of PCOS, and studies have reported a significant rise in serum level of VEGF in the PCOS patients \[[@CR16]--[@CR18]\]. Additionally, the overexpression of VEGF gene in the polycystic ovarian stroma also reveals the critical role of this gene in the pathophysiology of PCOS \[[@CR19]\].

Recent researches have focused on the correlation between VEGF gene polymorphism and PCOS, with rs2010963 (G \> C), rs833061 (T \> C), rs3025039 (C \> T), rs699947 (A \> C), and rs1570360 (A \> G) extensively investigated for their potential relationship to PCOS risk \[[@CR20]--[@CR29]\]. However, due to different ethnicities and small study sample size, evidence obtained from the different studies remains inconclusive and their results are even controversial. Therefore, we undertook this meta-analysis to explore more comprehensively the relationship between VEGF gene polymorphism and the risk of PCOS by combining existing research results.

Materials and methods {#Sec2}
=====================

Literature search {#Sec3}
-----------------

After formulating the search strategy, we systematically searched the databases of PubMed, EMBASE, Web of Science (WOS), Chinese National Knowledge Infrastructure (CNKI) and Wan Fang to collect potentially eligible case-control studies related to VEGF gene polymorphisms and the risk of PCOS. The last retrieval was conducted on October 1, 2019. The search terms were as follows: ("VEGF" OR "vascular endothelial growth factor") and ("PCOS" OR "Polycystic ovary syndrome") and ("mutation" OR "variant" OR "polymorphism" OR "genotype" OR "allele" OR "gene" OR "snp"). To avoid the omission of relevant research, references in the eligible literature after retrieval were also browsed and manually retrieved.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The studies included in this meta-analysis must meet the following criteria: (a) Case-control studies covered the relationship between VEGF gene polymorphisms and risk of PCOS. (b) The sample size, genotype distribution, and genotype frequency of the case and control groups were directly provided in the document, or the literature contained available original data that could be converted into OR value and 95%CI for the case and control groups. (c) The diagnosis of PCOS patients in the case group must conform to one of the following three diagnostic criteria: NIH, Rotterdam, and AE-PCOS Society \[[@CR30]--[@CR32]\] (d). The inclusion criteria for the control group were clear and definite. (e) If multiple articles based on the same case and control population were published by the same author or research center, only relevant researches in the latest publication time would be incorporated.

Studies were excluded on the basis of the following criteria: (a) There was no clear definition of polycystic ovary syndrome in the literature, and no clear diagnostic criteria were available for enrolled patients in the case group. (b) The specific genotype data of the case group and the control group were not provided, or the genotype frequency of the case group and the control group could not be calculated by the original data in the literature. (c) Conference papers, case reports, literature reviews or animal researches were ruled out.

Data extraction {#Sec5}
---------------

Two reviewers (Jiahui Zhao and Da Li) read screened independently the eligible relevant literature according to the inclusion and exclusion criteria. When the two researchers disagreed about whether or not a study should be included, they would try to resolve it through discussion. If they could not reach a consensus, the final decision would be made by a third researcher (Lisha Tang). For the included literature after screening, the following data were mainly extracted: first author, publication year, nationality, ethnicity, PCOS diagnostic criteria adopted, inclusion criteria of the control group, source of control, genotyping method, single nucleotide polymorphisms (SNPs) investigated in the study, sample size and genotype distribution of the case group and the control group.

Quality assessment {#Sec6}
------------------

The literature quality was evaluated by Newcastle-Ottawa Scale (NOS) \[[@CR33]\]. The NOS evaluation criterion of case-control study included 9 items (1 point for each item, 9 points in total). The specific scores involved: (1) selection of the case group and control group (4 points) based on appropriate definition and diagnosis of the case, representativeness of the case, selection of control, and definition of control; (2) comparability between the case group and control group (2 points); and (3) exposure evaluation of the case group and control group (4 points). If the study satisfied the evaluation score at 7 points or above, the quality of the literature was thought to be high; if the research evaluation score ranged 4--6, the quality of the literature was medium; and if the score wass \< 4, the literature quality was considered low.

Statistical analysis {#Sec7}
--------------------

Meta-analysis was mainly performed using Revman5.3 software by the Cochrane Collaboration. The strength of association between VEGF polymorphisms and susceptibility of PCOS was evaluated by calculating Odds ratios (OR) and its 95% confidence intervals (CIs) under five gene comparison models. For example, the correlation between rs2010963 (G \> C) polymorphism and PCOS risk was measured and assessed under the following models: allele model (C vs. G), dominant model (GC + CC vs. GG), heterozygous model (GC vs. GG), recessive model (CC vs. GC + GG) and homozygous model (CC vs. GG). The heterogeneity between studies was quantitatively determined by I^2^ statistic. If I^2^ was lower than 50%, which indicated that the heterogeneity was low, the fixed-effect model would be applied for meta-analysis. If statistical heterogeneity between studies existed (I^2^ \> 50%), the source of heterogeneity would be further analyzed, and the random effect model would be adopted. In addition to overall analysis, subgroup analyses stratified by ethnicity and source of control were also performed. Since all of the included literature adopted the Rotterdam diagnostic criteria for the enrolled patients of case groups, there was no subgroup analyses based on different diagnostic criteria. If there was only one article in a subgroup, no separate analysis would be performed.

The possible publication bias was first evaluated by observing the symmetry of the funnel plots. The Stata14.0 software (STATA Corporation, College Station, TX) was further applied to perform the Begg's and Egger's test procedures to assess potential publication bias. The genotype distribution of the control group was calculated by χ^2^ test to ascertain whether the control group was consistent with Hardy-Weinberg equilibrium (HWE).

Traditional meta-analysis methods have no way to assess the adequacy of the overall sample size of the included studies. When the overall sample size is not sufficient, the final pooled results obtained are not reliable enough, especially the positive results obtained by meta-analysis. Statistical results based on insufficient sample size increase the likelihood of false positive results (Type 1 error). Therefore, in the present study, we adopted trial sequential analysis (TSA) method to determine whether the overall sample size of the included studies was sufficient and whether the overall results obtained were reliable. Trial sequential analysis (TSA) was performed by using the TSA v0.9.5.10 Beta software \[[@CR34]\]. For the positive results obtained from meta-analysis, TSA method was applied to analyze the reliability of the results and examine whether the sample size was sufficient. If the cumulative Z curve crossed trial sequential monitoring boundary, the result was considered stable and reliable. The sufficiency of overall sample size was estimated based on whether the cumulative Z-curve exceeded the required information size (RIS).

Ethical approval {#Sec8}
----------------

The meta-analysis was performed by summarizing data from previous studies. Therefore, no ethical approval was required.

Results {#Sec9}
=======

Study selection and characteristics {#Sec10}
-----------------------------------

A total of 129 articles were obtained through initial literature retrieval. After excluding 25 duplicates, the remaining 104 papers were filtrated by reading their titles and abstracts. After further screening, totally 12 papers entered the full-text acquisition and detailed screening. After excluding a repetitive study based on the same case group and another article focusing on the association between VEGF gene polymorphisms and insulin resistance in patients with PCOS, 10 articles met the inclusion criteria and eventually merged into the study. A total of 1347 PCOS cases and 1378 controls were included in the 10 included studies \[[@CR20]--[@CR29]\]. This analysis spanned seven regions and two ethnic groups, Caucasian and Asian. In all the incorporated studies, the diagnostic criteria of PCOS patients in the case group were Rotterdam criteria, and the inclusion criteria of the control group were clearly explained. The NOS score of all the included studies was higher than 6 points, and most of them explored the relationship between multiple SNPs and PCOS susceptibility. Therefore, in the final pooled analysis, 6 studies were eligible for VEGF gene rs2010963 polymorphism and PCOS risk (952 cases and 960 controls), 6 for rs833061 polymorphism and PCOS risk (936 cases and 1010 controls), 5 for rs3025039 polymorphism and PCOS risk (769 cases and 779 controls), 5 for rs699947 polymorphism and PCOS risk (779 cases and 834controls), and 5 for rs1570360 polymorphism and PCOS risk (752 cases and 779 controls).

The flowchart of selection and inclusion process is displayed in Fig. [1](#Fig1){ref-type="fig"}, and the general characteristics of all included studies in Table [1](#Tab1){ref-type="table"}. Table [2](#Tab2){ref-type="table"} shows the detailed genotype distributions of each group and the *p* value of Hardy-Weinberg equilibrium (HWE) in each control group. The Newcastle-Ottawa Scale scores for all the included studies are shown in Table [3](#Tab3){ref-type="table"}. Fig. 1Flow diagram of selection and inclusion processTable 1Characteristics of included studiesAuthorYearRegionEthnicityPCOS Diagnostic criteriaInclusion criteria for the control groupControl sourceGenotyping methodSNPNOSAlmawi \[[@CR20]\]2016BahrainCaucasianRotterdamage-and ethnically-matched; testosterone levels were within range (0.4--3.5 nmol/L) in the menstrual cycle follicular phase; no metabolic or endocrine diseases; BMI were between 18 and 45 kg/m^2^;without recent illness; without treatment may affect carbohydrate metabolism or hormonal levels within 3 months; without using anti-hypertensive, oral contraceptive, anti-inflammatory and lipid-lowering drugsPBRT-PCRrs2010963rs833061rs3025039rs699947rs15703608Bao \[[@CR21]\]2019IndiaAsianRotterdamage-and ethnically-matched; testosterone levels were within range (0.4--3.5 nmol/L) in the menstrual cycle follicular phase; no metabolic or endocrine diseases; BMI were between 18 and 45 kg/m^2^;without recent illness; without using anti-hypertensive, oral contraceptive, anti-inflammatory and lipid-lowering drugsPBRT-PCRrs2010963rs833061rs3025039rs699947rs15703606Ben Salem \[[@CR22]\]2016TunisiaCaucasianRotterdamwomen with regular menstrual cycles and no evidence of hirsutism, acne, alopecia, or endocrinopathies; without treatment may affect carbohydrate metabolism or hormonal levels within 3 monthsPBRT-PCRrs833061rs3025039rs699947rs15703607Ding \[[@CR28]\]2009ChinaAsianRotterdamwomen with regular menstrual cycles; with normal ovarian morphology; without treatment may affect carbohydrate metabolism or hormonal levels within 3 months; no metabolic or endocrine diseases;HBPCRrs30250396Gomes \[[@CR23]\]2019BrazilCaucasianRotterdamage- matched; fertile women with no history of hyperandrogenism, menstrual dysfunction, infertility, or sonographic signal of PCOS; without using contraceptives, antiandrogens, statins, glucocorticoids or infertility medications within 6 monthsPBPCR-RFLP(rs699947)RT-PCR(rs1570360)rs699947rs15703606Guruvaiah \[[@CR24]\]2014IndiaAsianRotterdamfertile women with regular menstrual cycles and had a successful pregnancy record; with normal ovarian morphology confirmed by ultrasoundPBPCRrs2010963rs8330617Huang \[[@CR25]\]2019ChinaAsianRotterdamwomen with normal menstrual cycles and had at least one successful pregnancy history; without endocrine disorders, family history of diabetes or sonographic signs of PCOSHBPCR-LDRrs2010963rs8330617Lee \[[@CR26]\]2008KoreaAsianRotterdamBMI-matched; with regular menstrual cycles; with normal ovarian morphology confirmed by ultrasoundPBPCRrs2010963rs30250396Li \[[@CR29]\]2014ChinaAsianRotterdamfertile women with regular menstrual cyclesHBPCR-RFLPrs15703606Vural \[[@CR27]\]2009TurkeyCaucasianRotterdamfertile women without hyperandrogenism, history of menstrual dysfunction, infertility or sonographic signs of PCOS.PBPCRrs2010963rs833061rs6999476*PCR* polymerase chain reaction, *RFLP* restriction fragment length polymorphism, *RT-PCR* real time polymerase chain reaction, *PCR-LDR* polymerase chain reaction-ligase detection reaction, *NOS* Newcastle--Ottawa scale, *PB* Population-based, *HB* Hospital-based, *BMI* body mass index, *PCOS* polycystic ovary syndromeTable 2Genotype distribution and HWESNPAuthorSample sizeCase GenotypeControl genotypeHWECaseControlGGGCCCGGGCCCY/N(***p***)**rs2010963**Almawi38239318314257161190420.45Bao55522811162612140.47Guruvaiah1261307046105259190.73Huang1181306045134764190.71Lee1341004660263445200.47Vural137155904431123940.78**SNPAuthorSample sizeCase GenotypeControl genotypeHWECaseControlTTTCCCTTTCCCY/N(*p*)rs833061**Almawi38239313017478132190710.91Bao5552329142411170.06Ben Salem1181503355304276320.82Guruvaiah1261304059273372250.20Huang118130634510804280.44Vural1371555564185274290.77**SNPAuthorSample sizeCase GenotypeControl genotypeHWECaseControlCCCTTTCCCTTTY/N(*p*)rs3025039**Almawi3823932968153186870.78Bao5552319152411170.10Ben Salem118150892721271940.005Ding808445350543000.04Lee134100893545931100.06**SNPAuthorSample sizeCase GenotypeControl genotypeHWECaseControlAAACCCAAACCCY/N(*p*)rs699947**Almawi38239313518364165178500.48Bao5552345162609170.17Ben Salem1181503563204577280.62Gomes87842738221841250.70Vural1371555263225278250.64**SNPAuthorSample sizeCase GenotypeControl genotypeHWECaseControlAAAGGGAAAGGGY/N(*p*)rs1570360**Almawi38239319714045218131440.09Bao5552241318309130.03Ben Salem1181505742197557180.17Gomes878456247523110.12Li11010078293653050.53*HWE* Hardy--Weinberg equilibriumTable 3Quality assessment using the Newcastle--Ottawa scaleStudyAdequacy of Case DefinitionRepresentativeness of the CasesSelection of ControlsDefinition of ControlsCompara- bilityAscertainment of exposureSame method of ascertainmentNon-Response ratescoreAlmawi 2016 \[[@CR20]\]\*\*\*\*\*\*\*\*8Bao 2019 \[[@CR21]\]\*\*\*\*\*\*6Ben Salem 2016 \[[@CR22]\]\*\*\*\*\*\*\*7Ding 2009 \[[@CR28]\]\*\*\*\*\*\*6Gomes 2019 \[[@CR23]\]\*\*\*\*\*\*6Guruvaiah 2014 \[[@CR24]\]\*\*\*\*\*\*\*7Huang 2019 \[[@CR25]\]\*\*\*\*\*\*\*7Lee 2008 \[[@CR26]\]\*\*\*\*\*\*6Li 2014 \[[@CR29]\]\*\*\*\*\*\*6Vural 2009 \[[@CR27]\]\*\*\*\*\*\*6

Meta-analysis results {#Sec11}
---------------------

### Meta-analysis of association between VEGF gene rs2010963 polymorphism and PCOS susceptibility {#Sec12}

The main results of the overall and subgroup meta-analysis for VEGF gene polymorphisms and PCOS susceptibility are presented in Table [4](#Tab4){ref-type="table"}. Six studies had 952 cases and 960 controls for VEGF rs2010963 polymorphism. Four of them were based on the Asian populations and two on the Caucasian populations. Overall, the pooled results based on the whole population revealed significant correlation between VEGF rs2010963 variation and decreased PCOS susceptibility under 2 gene comparison models (Dominant model: OR = 0.78, 95%CI: 0.65--0.94, *P* = 0.008, I^2^ = 49%; Heterozygote model: OR = 0.75, 95%CI: 0.61--0.91, *P* = 0.04, I^2^ = 48%). When the studies were stratified by ethnicity, significantly decreased risk of PCOS was observed in the Asian populations under 3 gene comparison models (Allele model: OR = 0.76, 95%CI: 0.63--0.93, P = 0.008, I^2^ = 39%; Dominant model: OR = 0.69, 95%CI: 0.50--0.95, *P* = 0.02, I^2^ = 26%; Heterozygote model: OR = 0.68, 95%CI: 0.50--0.92, *P* = 0.01, I^2^ = 0%). No significant association was found between VEGF rs2010963 polymorphism and PCOS susceptibility in the Caucasian ethnicities and stratified subgroup analyses based on source of control. Figure [2](#Fig2){ref-type="fig"} shows the forest plot of the association between VEGF gene rs2010963 polymorphism and PCOS susceptibility. Table 4Main results of overall and subgroup analyses for VEGF polymorphisms and PCOSGroup/ SubgroupSample size (Case/Control)Allele modelDominant modelHeterozygote modelRecessive modelHomozygote modelOR (95%CI)***p***I^**2**^OR (95%CI)***p***I^**2**^OR (95%CI)***p***I^**2**^OR (95%CI)***p***I^**2**^OR (95%CI)***p***I^**2**^**rs2010963**Total952/9600.88 \[0.76,1.01\]0.0648%0.78 \[0.65, 0.94\]**0.008**49%0.75 \[0.61, 0.91\]**0.004**48%1.03 \[0.79, 1.36\]0.8224%0.88 \[0.65, 1.17\]0.3828%Caucasian519/5480.99 \[0.82, 1.20\]0.9424%0.98 \[0.55, 1.73\]0.9375%0.93 \[0.44, 1.96\]0.8584%1.41 \[0.93, 2.12\]0.100%1.17 \[0.76, 1.80\]0.480%Asian433/4120.76 \[0.63, 0.93\]**0.008**39%0.69 \[0.50, 0.95\]**0.02**26%0.68 \[0.50, 0.92\]**0.01**0%0.80 \[0.55, 1.16\]0.240%0.68 \[0.46, 1.02\]0.0621%PB834/8300.92 \[0.79, 1.06\]0.2445%0.82 \[0.68, 1.00\]0.2948%0.83 \[0.59, 1.16\]0.2751%1.09 \[0.81, 1.47\]0.5629%0.95 \[0.69, 1.30\]0.7324%**rs833061**Total936/10100.98 \[0.86, 1.12\]0.8025%0.93 \[0.77,1.12\]0.456%0.91 \[0.74,1.11\]0.350%1.06 \[0.84,1.33\]0.630%0.97 \[0.75,1.26\]0.830%Caucasian637/6980.99 \[0.84, 1.15\]0.8522%0.93 \[0.74,1.16\]0.510%0.90 \[0.71,1.15\]0.40%1.06 \[0.81,1.40\]0.6627%1.00 \[0.73,1.35\]0.9828%Asian299/3120.96 \[0.68, 1.37\]0.8351%0.90 \[0.54,1.49\]0.6754%0.93 \[0.64,1.33\]0.6847%1.05 \[0.68,1.62\]0.840%0.92 \[0.57,1.48\]0.730%PB818/8800.95 \[0.83, 1.09\]0.4810%0.87 \[0.71,1.07\]0.180%0.85 \[0.68,1.06\]0.140%1.04 \[0.82,1.32\]0.740%0.94 \[0.72,1.23\]0.630%**rs3025039**Total779/8340.97 \[0.68, 1.39\]0.8865%1.07 \[0.73, 1.57\]0.7358%1.21 \[0.95, 1.55\]0.1242%0.59 \[0.34, 1.02\]0.060%0.56 \[0.32, 0.99\]**0.05**0%Caucasian500/5431.22 \[0.93, 1.60\]0.160%1.35 \[1.00, 1.83\]**0.05**10%1.43 \[1.04, 1.95\]**0.03**33%0.70 \[0.27, 1.82\]0.460%0.76 \[0.29, 1.97\]0.570%Asian269/2360.79 \[0.48, 1.29\]0.3563%0.83 \[0.49, 1.41\]0.4952%0.94 \[0.63, 1.39\]0.7526%0.54 \[0.28, 1.05\]0.0748%0.48 \[0.24, 0.97\]**0.04**36%PB689/6950.91 \[0.60, 1.39\]0.6871%1.00 \[0.63, 1.60\]0.9966%1.13 \[0.72, 1.76\]0.6055%0.59 \[0.34, 1.02\]0.060%0.56 \[0.32, 0.99\]**0.05**0%HWE (yes)571/5450.79 \[0.50,1.25\]0.3270%0.84 \[0.51,1.40\]0.5163%1.06 \[0.79,1.41\]0.7141%0.58 \[0.33,1.04\]0.074%0.55 \[0.30,0.99\]**0.05**0%**rs699947**Total779/8341.03 \[0.90, 1.19\]0.6549%1.03 \[0.84, 1.26\]0.7848%1.01 \[0.81, 1.26\]0.9137%1.07 \[0.82, 1.38\]0.620%1.06 \[0.80, 1.41\]0.6936%Caucasian724/7821.00 \[0.80, 1.25\]0.9951%1.07 \[0.87, 1.32\]0.5349%1.05 \[0.83, 1.31\]0.7030%1.09 \[0.83, 1.43\]0.520%1.11 \[0.82, 1.51\]0.4944%**rs1570360**Total752/7791.11 \[0.95, 1.30\]0.200%1.15 \[0.94, 1.41\]0.1711%0.69 \[0.37, 1.27\]0.2382%1.23 \[0.89, 1.70\]0.2115%1.29 \[0.92, 1.80\]0.1413%Caucasian587/6271.12 \[0.94, 1.34\]0.190%1.18 \[0.94, 1.49\]0.140%0.58 \[0.24, 1.37\]0.2188%1.26 \[0.88, 1.81\]0.2140%1.31 \[0.90, 1.90\]0.1623%Asian165/1521.08 \[0.53, 2.23\]0.8373%1.11 \[0.49, 2.53\]0.7966%0.95 \[0.24, 3.81\]0.9582%1.12 \[0.55, 2.30\]0.7527%1.22 \[0.58, 2.57\]0.6050%PB642/6791.16 \[0.98, 1.37\]0.080%1.22 \[0.98, 1.52\]0.070%0.75 \[0.35, 1.58\]0.4484%1.29 \[0.92, 1.79\]0.1413%1.36 \[0.96, 1.93\]0.080%HWE (yes)697/7271.08 \[0.91,1.27\]0.390%1.12 \[0.90,1.38\]0.308%0.56 \[0.29,1.09\]0.0984%1.19 \[0.84,1.69\]0.3233%1.23 \[0.85,1.76\]0.2725%*VEGF* vascular endothelial growth factor, *PCOS* polycystic ovary syndrome, *OR* odds ratio, *CI* confidence interval, *NA* not available, *HB* hospital-based, *PB* population-based. The bold values represent statistically significant differencesFig. 2Forest plots for association between VEGF gene rs2010963 polymorphism and PCOS susceptibility in different genetic models (**a**: allele model **b**:dominant model **c**:heterozygous model **d**:recessive model **e**:homozygous model)

### Meta-analysis of association between VEGF gene rs833061 polymorphism and PCOS susceptibility {#Sec13}

Six studies had 936 cases and 1010 controls for VEGF rs2010963 polymorphism, 3 of which were based on the Asian populations and another 3 on the Caucasian populations. There was no significant correlation found between VEGF gene rs833061 polymorphism and risk of PCOS, whether based on aggregate analysis of all populations or subgroup analyses based on different ethnicities and sources of control.

### Meta-analysis of association between VEGF gene rs3025039 polymorphism and PCOS susceptibility {#Sec14}

Five studies had 769 cases and 779 controls for VEGF rs3025039 polymorphism, 3 of which were based on the Asian populations and 2 on the Caucasian populations. Overall, the pooled results based on the whole population revealed significantly negative correlation between VEGF rs2010963 polymorphism and PCOS risk under Homozygote model (OR = 0.56, 95%CI: 0.32--0.99, *P* = 0.05, I^2^ = 0%), Based on ethnic stratification, significantly increased risk of PCOS was observed in the Caucasian populations under 2 gene comparison models (Dominant model: OR = 1.35, 95%CI: 1.00--0.95, P = 0.05, I^2^ = 10%; Heterozygote model: OR = 1.43, 95%CI: 1.04--1.95, *P* = 0.03, I^2^ = 33%). However, in the Asian populations, there was negative correlation between VEGF rs2010963 polymorphism and PCOS risk under Homozygote model (OR = 0.48, 95%CI: 0.24--0.97, *P* = 0.04, I^2^ = 36%). Moreover, subgroup analysis based on source of control indicated that VEGF rs3025039 polymorphism was related to decreased PCOS risk in the population-based group under Homozygote model (OR = 0.56, 95%CI: 0.32--0.99, *P* = 0.05, I^2^ = 0%).

### Meta-analysis of association between VEGF gene rs699947 polymorphism and PCOS susceptibility {#Sec15}

Five studies had 779 cases and 834 controls for VEGF rs699947 polymorphism. Four of them were based on the Caucasian populations. There was no significant correlation between VEGF gene rs699947 polymorphism and risk of PCOS, whether based on analysis by synthesis of all populations or subgroup analyses based on the Caucasian ethnicities.

### Meta-analysis of association between VEGF gene rs1570360polymorphism and PCOS susceptibility {#Sec16}

Five studies had 752 cases and 779 controls for VEGF rs1570360 polymorphism. Three of them were based on the Caucasian populations and two on the Asian populations. No significant association was identified between VEGF gene rs1570360 polymorphism and risk of PCOS, whether based on aggregate analysis of all populations or subgroup analyses based on different ethnicities and sources of control.

Publication bias {#Sec17}
----------------

Statistical association was found between VEGF rs2010963 and rs3025039 polymorphisms and PCOS susceptibility. The potential publication bias was first evaluated by observing the funnel plot obtained through Revman5.3 software. Funnel plots showed no conspicuous visual asymmetry (Fig. [3](#Fig3){ref-type="fig"}). Begg's test and Egger's test were applied to further detect potential publication bias. The results of Begg's test and Egger's test also revealed no significant evidence of publication bias. Table [5](#Tab5){ref-type="table"} summarizes the main results of Begg's test and Egger's test. Fig. 3Funnel plot for the association betweenVEGF gene rs2010963 polymorphism and PCOS risk (**a**: allele model **b**:dominant model **c**:heterozygous model **d**: recessive model **e**:homozygous model)Table 5Summary of publication bias testsSNPComparison model typebegg's textegger's textz***p*** valuet***p*** value**rs2010963**Allele model−0.190.8510.040.969Dominant model0.560.5730.480.655Heterozygote model0.560.5761.310.261Recessive model−0.560.573−2.010.115Homozygote model−0.940.348−1.310.260**rs833061**Allele model0.190.851−0.500.641Dominant model−0.940.3483.150.035Heterozygote model−1.320.188−0.450.679Recessive model−0.190.851−0.550.608Homozygote model−0.190.851−0.330.760**rs3025039**Allele model0.490.624−0.010.993Dominant model0.001.000−0.220.837Heterozygote model0.490.624−0.230.835Recessive model−1.360.174−0.660.576Homozygote model−0.680.4971.170.362**rs699947**Allele model−1.470.142−5.820.010Dominant model−1.470.142−5.190.014Heterozygote model−0.980.327−3.590.037Recessive model−1.470.142−5.070.015Homozygote model−1.470.142−10.900.002**rs1570360**Allele model0.980.3270.240.828Dominant model0.001.000−0.430.696Heterozygote model−0.490.624−0.500.651Recessive model1.470.1421.490.233Homozygote model1.470.1421.430.249

Sensitivity analysis {#Sec18}
--------------------

Sensitivity analysis was performed to assess the influence of each individual study on the overall pooled results. By sequentially removing individual study, no statistical variation of pooled OR was observed. The results of sensitivity analysis indicated that the pooled ORs of this meta-analysis were stable (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Sensitivity analysis results between VEGF gene rs2010963 polymorphism and PCOS risk (**a**: allele model **b**:dominant model **c**:heterozygous model **d**: recessive model **e**:homozygous model)

Trial sequential analysis {#Sec19}
-------------------------

Trial sequential analysis was performed for each gene comparison model with statistically significant differences obtained through previous calculation to investigate whether the pooled results we obtained were stable and reliable. Under the dominant model of rs2010963, although the cumulative Z curve did not intersect with the trial sequential monitoring boundary, the cumulative case samples exceeded the required information size (RIS), suggesting that the accumulated sample size was sufficient and the pooled positive result was credible. Under the heterozygote model of rs2010963, the cumulative Z curve passed through the traditional boundary threshold, meanwhile crossed the trial sequential monitoring boundary, and confirmed a reliable conclusion although the cumulative sample size did not transcend the required information size (RIS). In other gene comparison models that yielded positive results, the cumulative Z curve did not cross the sequential trial monitoring boundary, and the sample size did not reach RIS, demonstrating that the pooled results possibly were not solid enough. Figure [5](#Fig5){ref-type="fig"} shows the results of trial sequential analysis under the dominant model and the heterozygote model of rs2010963. Fig. 5Trial sequential analysis results of the association between VEGF gene rs2010963 polymorphism and PCOS risk (**a**:dominant model **b**: heterozygous model)

Discussion {#Sec20}
==========

Polycystic ovary syndrome (PCOS) is a female endocrine disorder with complex etiology. Currently, the widely adopted diagnostic criteria are Rotterdam criteria: rare ovulation or anovulation, clinical or biochemical hyperandrogenemia, and ovarian polycystic changes determined by ultrasound. Patients with two of three in the criteria and without other diseases that may cause hyperandrogenemia could be diagnosed with PCOS \[[@CR30]\]. The prominent pathophysiological features of PCOS are hyperplasia and hypervascularity of the ovarian theca interna and stroma \[[@CR2]\]. Angiogenesis in the ovary is essential for follicular growth, ovulation, and subsequent luteal development and regression. Increasing evidence demonstrates that there are multiple dysregulation of angiogenic factors in PCOS, including vascular endothelial growth factor, angiogenin, platelet-derived growth factor, transforming growth factor-alpha, and basic fibroblast growth factor. VEGF is one of the major regulators of angiogenesis, and its important role in physiological and pathological angiogenesis has been proved. It is the most extensively studied angiogenic factor related to the pathophysiology of PCOS \[[@CR35]\]. In the female reproductive system, macrophages and granulosa cells are the main sources of VEGF production. As a homologous dimeric glycoprotein hormone that binds heparin, VEGF can effectively promote vascular formation and improve vascular permeability \[[@CR36]\]. VEGF protein family consists of 6 members, namely VEGF (also known as VEGFA), VEGFB, VEGFC, VEGFD, VEGFE and placenta growth factor (PLGF), with molecular weight ranging from 35 kDa to 45 kDa. VEGF is recognized as a "central regulator" of angiogenesis due to its ability to specifically promote vascular endothelial division, proliferation and migration, and is the most potent angiogenic factor \[[@CR36]--[@CR39]\].

VEGF protein is known to be closely related to the pathogenesis of PCOS. Serum VEGF levels are significantly elevated in PCOS patients \[[@CR16]--[@CR18]\]. High levels of serum VEGF result in a higher number of active granuloas lutein cells (GLCs), increase secretion of GLCs, and up-regulate VEGF gene expression \[[@CR40]\]. In addition, the expression of VEGF in the stromal hyperplasia of PCOS is significantly increased, resulting in an increase in microvascular permeability, and a large number of neovascularization may lead to dysplasia of the ovarian producing androgen. VEGF gene is located at 6p21.3, with a total length of about 14 KB, and is alternately composed of 8 exons and 7 introns. There are at least 30 single nucleotide polymorphisms (SNPs) in the coding region of VEGF gene. Based on previous studies, rs2010963 and rs3025039 mutation sites have been proved to alter the plasma level of VEGF \[[@CR41], [@CR42]\]. The correlation between VEGF gene polymorphisms and the risk of PCOS has attracted growing attention in recent years, among which the most widely investigated SNPs are rs2010963 (G \> C), rs833061 (T \> C), rs3025039 (C \> T), rs699947 (A \> C), and rs1570360 (A \> G), but the results from different studies remain highly controversial. For example, in studies on the correlation between rs2010963 and PCOS susceptibility, 3 studies reported no significant correlation between the two, while the other 3 studies showed a reduced risk of PCOS in C allele carriers. In the studies on the correlation between rs833061 and PCOS susceptibility, except that BAO found that there was a significant statistical significance between this SNP and PCOS susceptibility, all the other 5 studies revealed that it was not related to the risk of PCOS. Therefore, this meta-analysis was conducted to comprehensively evaluate the relationship between VEGF gene polymorphisms and PCOS risk based on the data in the existing literature. According to the NOS standard, all 10 incorporated studies were considered to have high-quality. In the present study, the results of the pooled analysis showed a significant correlation between VEGF rs2010963 variability and decreased susceptibility to PCOS. Subgroup analysis based on different ethnic stratification showed that the negative correlation between rs2010963 mutation and PCOS susceptibility only appeared in the Asian races, and there was no significant correlation in the Caucasian populations. The pooled analysis of the association between the VEGF gene rs3025039 polymorphism and the risk of PCOS showed that this SNP increased the risk of PCOS in the general population. Subgroup analysis based on different ethnicities showed that the rs3025039 polymorphism in the Caucasian populations was also associated with an increased risk of PCOS. In the Asian populations, the VEGF gene rs3025039 polymorphism reduced the risk of PCOS. Therefore, our results showed that the correlation between VEGF gene polymorphisms and the risk of PCOS in different populations may be quite different, suggesting that further experimental studies are needed to explore the possible underlying reasons for this difference.

It must be recognized that this meta-analysis has some possible limitations. First, the number of articles included in the study was small, and the overall number of patients in the case group and control group was low. Some subgroup analyses were unable to perform data analysis because only one study was included, thus limiting the reliability of summary results. Secondly, the previous studies on VEGF gene polymorphisms and PCOS risk only contained two ethnicities, lacking relevant studies on other races. Third, although the inclusion criteria for the control group were clearly stated in all studies, the inclusion criteria for different studies were not the same. For example, in some studies, the inclusion criteria for the control group were healthy women of childbearing age, while in others the criteria detailed a history of successful childbearing and a recent absence of any medications that might affect hormone levels. As PCOS is a disease with complex etiology, its incidence is related to many factors, such as obesity and insulin resistance. Due to the absence of relevant patient data based on the two factors in the original study literature, we did not conduct subgroup stratification analysis based on factors such as whether the patient was obese or not and the severity of insulin resistance.

Despite some limitations, this meta-analysis still has several highlights. To date, this is the first known meta-analysis focused on the correlation between VEGF gene polymorphisms and PCOS risk. Through the establishment of strict inclusion and exclusion criteria, a total of 10 studies were included in this meta-analysis, involving 1347 PCOS cases and 1378 controls. The study spanned seven regions and included both Caucasian and Asian populations. We systematically evaluated the effect of VEGF gene polymorphism on the occurrence of PCOS. At the same time, in most gene comparison models, the calculated inter-study heterogeneity was low, indicating the results of this meta-analysis were stable. In addition, the results of trial sequential analysis (TSA) also demonstrate the correlation between rs2010963 and decreased risk of PCOS obtained through this current meta-analysis was stable and reliable. Many previous studies have suggested that multiple SNPs of VEGF gene increase the risk of diseases such as ovarian malignancies, hypertensive disorder of pregnancy, and idiopathic recurrent pregnancy loss, and thereafter have been confirmed by multiple meta-analyses. Our meta-analysis results revealed certain VEGF gene polymorphisms had a distinct different impact on the pathogenesis of PCOS in contrast to its role in the pathogenesis of other female reproductive system disorders \[[@CR43]--[@CR45]\]. There was a significant correlation between VEGF rs2010963 and decreased PCOS susceptibility, suggesting VEGF rs2010963 could be a protective factor for the risk of PCOS.

In conclusion, this study establishes a significant correlation between the variation of VEGF rs2010963 and decreased PCOS susceptibility in the entire population; subgroup analysis shows this association only occurs occurred in Asian populations. The mutation of VEGF gene rs3025039 may also decrease the risk of PCOS in the overall population; subgroup analysis based on different populations shows that rs3025039 polymorphism is also associated with decreased risk of PCOS in the Asian populations, while in the Caucasian populations rs3025039 polymorphism of VEGF gene enhances the risk of PCOS. More well-designed studies involving more cases will be needed in the future to confirm this inference.

CI

:   Confidence interval

HWE

:   Hardy--Weinberg equilibrium

OR

:   Odds ratio

PCOS

:   Polycystic ovarian syndrome

SNP

:   Single nucleotide polymorphism

VEGF

:   Vascular endothelial growth factor

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

None.

JZ and LT conceived and designed the study. DL and JZ extracted the data. DL performed the statistical analysis. JZ wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

This work was supported by Jiangsu Basic Research Program (Natural Science Foundation, BK20161298), Jiangsu Commission of Health (H2018014).

The current study was based on results of relevant published studies.

Not applicable.

Not applicable.

The authors declare that they have no competing interests.
